Account
Inquiry
Tirzepatide 15mg is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has shown significant potential in metabolic research. This synthetic peptide demonstrates superior activity compared to single GLP-1 receptor agonists, with clinical studies indicating 8-12% body weight reduction potential.
The mechanism of action involves simultaneous activation of both GIP and GLP-1 receptors, which work synergistically to regulate glucose metabolism and promote weight loss. Research suggests that the addition of GIP activity may help mitigate the nausea typically associated with GLP-1 receptor activation, allowing for more aggressive dosing regimens.
Our Tirzepatide 15mg is supplied as a white lyophilized powder with 99% purity, meeting strict pharmaceutical grade standards. The product undergoes comprehensive quality control testing including HPLC analysis, water content determination, and heavy metals screening to ensure research consistency.
Preclinical studies indicate that Tirzepatide 15mg may influence multiple metabolic pathways, including glucose homeostasis, insulin sensitivity, and adipocyte function. The compound has shown particular promise in research models of type 2 diabetes and obesity-related metabolic disorders.
For research use only. Not for human consumption. Proper laboratory handling procedures should be followed at all times when working with this compound.
